fashion -WSS

fashion

author：entertainment 2025-08-11 02:15:16 - browse：89366

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： SAMSHA loosens regulations on methadone treatment centers

explore

WSS

Do digital therapeutics have a future in medicine?

A $475,000 price tag for a new cancer drug: crazy or meh?

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

The history of OxyContin, told through Purdue Pharma documents

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Woodcock on FDA’s accelerated approval and her next chapter

entertainment

fashion

focus

Anesthesiologist group: stop taking Ozempic before surgery

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

As demand for Covid shots wanes, Moderna seeks its next success

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

In age of alternative facts, a scholarly course on calling out crap

A $475,000 price tag for a new cancer drug: crazy or meh?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA drug safety: Singulair case shows systemic surveillance flaws

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Novo acquires Inversago for up to $1 billion

hotspot

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Newly revealed memo details efforts to keep Trump in power following election loss

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

hotspot

explore

leisure time

knowledge